Table 2.
Patient’s pharmacogenetic test results
| Gene | Genotype | Predicted Phenotype |
|---|---|---|
| CYP2C19 | *1/*2 | Intermediate Metabolizer |
| CYP2D6 | *1/*2 | Extensive (Normal) Metabolizer |
| CYP3A4/CYP3A5 | *1/*1; *1/*1 | Extensive (Normal) Metabolizer |
| UGT2B15 | *1/*1 | Extensive (Normal) Metabolizer |
| DRD2 | INS/DEL | Reduced Responder |
| HTR2C | C/C | Normal Expressor |
| MTHFR | C/C (C677T); A/A (A1298C) | Normal Activity |
CYP cytochromes P450, UGT uridine 5′-diphospho-glucuronosyltransferase, DRD2 dopamine receptor D2 gene, HTR2C 5-hydroxytryptamine receptor 2C gene, MTHFR methylene tetrahydrofolate reductase gene